Our Investment Focus & Portfolio

Investments in other technologies incl. Microbiome and Infectious Diseases

ArrePath
Centauri Therapeutics
Delonix
Glox
Obulytix
RiboX Therapeutics
smartbax GmbH
Topas Therapeutics

ArrePath

ArrePath

ArrePath is a Princeton (NJ)-based company that is developing a machine learning-powered discovery platform of novel mechanism of action anti-microbial resistant drugs. The platform utilizes bacterial autopsy image recognition-based machine learning to prioritize hits with novel MoA from high-throughput phenotypic screening to significantly accelerate the identification of hits, and thus allow the rapid discovery of novel MoA proprietary antibiotics.

Year of investment: 2021; BIVF Board Representative: Fei Shen
www.arrepath.com

Centauri Therapeutics

Centauri Therapeutics

Centauri Therapeutics is an immunotherapy company focused on the treatment of infectious diseases dedicated to antimicrobial resistance (AMR) research, using their Alphamer® platform to identify and progress novel antibacterial candidates through first-in-human trials, for difficult-to-treat infections. The Alphamer technology introduces an innovative drug mechanism that recruits and directs pre-existing antibodies specifically to pathogens, engaging both innate and adaptive immunity to elicit an immune response that clears the infection.

Year of investment: 2022; BIVF Board Representative: Johannes Zanzinger
www.centauritherapeutics.com

Delonix Bioworks

Delonix

Delonix Bioworks is a biotech company leveraging synthetic biology approaches and gene editing to develop the next generation medical solutions to infectious diseases and cancer. The company’s research programs focus on rational design and programming of bacteria as living medicines.

Year of investment: 2021; BIVF Board Representative: Yifang Cui

Glox Therapeutics

Glox Therapeutics

Initially built out of 20+ years of research, Glox Therapeutics has globally recognised expertise in elucidating bacteriocin structure and function and developing bacteriocin-based strategies to prevent and treat bacterial infections. The company is developing a pipeline of engineered precision bacteriocins targeting pathogens such as Pseudomonas aeruginosa and Klebsiella pneumoniae that cause serious infections associated with high levels of antimicrobial resistance (AMR) and mortality.

Year of investment: 2023; Investment Manager: Niklas Czeloth

Obulytix

Obulytix

Obulytix is a biotechnology company focused on the discovery and development of a groundbreaking class of enzyme-based antibiotics to combat the most severe antibiotic-resistant bacteria.

Armed with our expertise and great commitment, we're here to make a real difference. Our mission is to provide concrete solutions to this pressing global challenge and to save the lives of countless patients battling life-threatening conditions.

Year of investment: 2023; Investment Manager: Niklas Czeloth

RiboX Therapeutics

RiboX Therapeutics

RiboX Therapeutics is a Shanghai based Biotech Company focused on discovery and development of fully engineered circular RNA therapeutics - a new class of RNA medicines which can overcome current limitations of mRNA therapeutics and realize the full potential of RNA medicines. The company was founded by world-leading scientists from RNA biology and nanomedicine field. The management team are industrial veterans from Roche, Merck, Bayer with extensive experience in early discovery, drug delivery and translational medicine.

Year of investment: 2021; BIVF Board Representative: Frank Kalkbrenner

smartbax GmbH

smartbax GmbH

smartbax develops novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms. With the first-in-class compounds, the company targets the multi-drug resistant pathogens methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). The new class of antibiotic compounds is based on the research by Prof. Stephan Sieber and his team at Technical University Munich. smartbax GmbH was incorporated in 2021 and is based in Munich. Due to the increasing prevalence of resistance against marketed antibiotics, smartbax addresses a need which is growing dramatically.

Year of investment: 2021; BIVF Board Representative: Sebastian Kreuz
www.smartbax.de

Topas Therapeutics

Topas Therapeutics

Topas Therapeutics is a private Hamburg-based biotechnology company focused on developing peptide-loaded nanoparticles to address immuno-tolerization of major unmet clinical need, including autoimmune diseases, allergies and anti-drug antibodies. Topas’ technology platform induces antigen-specific immune tolerance by harnessing the liver’s natural immuno-tolerizing capabilities.

Year of investment: 2017; BIVF Board Representative: Sebastian Kreuz
topas-therapeutics.com